A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection.
Zennia Jean C GonzagaChristina MerakouAntonio DiGiandomenicoGregory P PriebeBernd H A RehmPublished in: Vaccines (2021)
Despite numerous efforts to develop an effective vaccine against Pseudomonas aeruginosa, no vaccine has yet been approved for human use. This study investigates the utility of the P. aeruginosa inherently produced polyhydroxyalkanaote (PHA) inclusions and associated host-cell proteins (HCP) as a particulate vaccine platform. We further engineered PHA inclusions to display epitopes derived from the outer membrane proteins OprF/OprI/AlgE (Ag) or the type III secretion system translocator PopB. PHA and engineered PHA beads induced antigen-specific humoral, cell-mediated immune responses, anti-HCP and anti-polysaccharide Psl responses in mice. Antibodies mediated opsonophagocytic killing and serotype-independent protective immunity as shown by 100% survival upon challenge with P. aeruginosa in an acute pneumonia murine model. Vaccines were stable at 4 °C for at least one year. Overall, our data suggest that vaccination with subcellular empty PHA beads was sufficient to elicit multiple immune effectors that can prevent P. aeruginosa infection.
Keyphrases
- pseudomonas aeruginosa
- immune response
- type iii
- single cell
- cystic fibrosis
- endothelial cells
- cell therapy
- high glucose
- drug induced
- acinetobacter baumannii
- liver failure
- type diabetes
- stem cells
- drug resistant
- electronic health record
- inflammatory response
- skeletal muscle
- high fat diet induced
- adipose tissue
- oxidative stress
- metabolic syndrome
- hepatitis b virus
- stress induced
- klebsiella pneumoniae
- candida albicans
- zika virus
- wild type
- visible light